Thought leaders are adopting Bionano in cyto
A consortium led by Dr. Brynn Levy at Columbia, who validated chromosomal microarray for cytogenetic use, is leading an AML clinical benchmark study. The consortium includes Penn State University, Harvard University, The Pathgroup, Mayo Clinic, University of Washington, and others.
Dr. Alex Hoischen (RUMC), a pioneer in bringing new technologies to the clinic, and Dr. Laila El Khattabi (Cochin Hospital Paris) are leading a group of European labs performing a clinical validation on constitutional disorder testing.
Dr. Guillermo Garcia-Manero, head of MD Anderson’s AML & MDS Moon Shot Program and Dr. Rashmi Kanagal-Shamanna, director of the hematopathology microarray facility, are performing a clinical benchmark study on patients with Myelodysplastic Syndrome.
Dr. Ravi Kolhe from Augusta University who clinically validated several diagnostic assays is developing a Lab Developed Test for cancer based on leukemia and glioblastoma samples.
Dr. Eddy Maher from NHS Lothian in Edinburgh, who introduced chromosomal microarray in the UK clinics, is running a clinical validation for cytogenetic testing and NHS certification.